english.prescrire.org > Prescrire International > N°127 - May 2012

n°127

May 2012

Issue Contents
Editorial

Free  All that glitters...

p.118
Clinical trial acronyms under the influence of marketing departments

Marketing Authorisations


Vernakalant (New Drug)

p.119-122
Too dangerous in atrial fibrillation

Sunitinib and pancreatic neuroendocrine tumours (New Indication)

p.123-125
More assessment needed

INN common-stem: -azepam, -azam, -azolam

p.125

Adverse Effects


Drug-induced colour vision disorders

p.126-128
Reduce the dose to avoid irreversible damage

Towards better reporting of adverse drug reactions

p.128-129
Improving the collection of reports

Neuroleptics: bedwetting

p.129
Under-reported

Romiplostim: leukaemia after myelodysplastic syndromes

p.129
An interim analysis of a clinical trial

Silodosin: erectile and ejaculatory disorders

p.129
There are safer options

Escitalopram: torsades de pointes

p.130
Same problem as with citalopram

Tianeptine: more cases of dependence

p.130
Intake in excess of recommended dose

Lenalidomide: second cancers

p.130
Beware off-label use

Reviews


Warts: frequent spontaneous clearance

p.131
Cryotherapy, salicylic acid or no treatment

Migraine attacks: paracetamol first

p.132
In about half of migraine sufferers

Anterior cruciate ligament rupture: no routine surgery

p.132
Progressive rehabilitation

Outlook


Free  Facts and figures. The finances of Association Mieux Prescrire

p.116-117
2011 Prescrire annual report

Free  2011 drug packaging review: too many dangers and too many patients overlooked

p.133-138

Free  Drug packaging: improvements needed to protect children

p.135

Free  Rebuilding regulation after the Mediator° disaster: drug regulatory agencies must tackle the issue of packaging

p.137

Free  No grants. No advertising. No conflicts of interest.

p.140

Masthead


Free  Masthead

p.114

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe